{"schema":"sb.node.v1","id":"sb:e/634a1238831829895f442344","kind":"entity","label":{"text":"wclc","locale":"en"},"identity":{"anchor":"label:en:wclc","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-08T17:31:13.825968+00:00","snapshot":"deploy cbe6d3891c15b71ee1fc14ceb7b06db92a7c2100"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":28,"separatePublishers":8,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-09-12","to":"2026-10-07","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.107: about 89% of mentions carry no typed assertion"]}},"dimensions":{"domains":["society_news","auto"],"activeDays":16,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/6e7cf521509965068948b425","kind":"observation","label":"Fierce Pharma · 2026-09-19 · Fierce Pharma Asia—China deals safe from COINS?; Key WCLC data; Legend’s new CEO","url":"https://www.fiercepharma.com/pharma/china-deals-safe-coins-act-key-wclc-data-legend-new-ceo"},{"id":"sb:o/f8df50c84565e5acf7e497af","kind":"observation","label":"PR Newswire · 2026-09-13 · Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026","url":"https://www.prnewswire.com/news-releases/ivonescimab-versus-pembrolizumab-in-first-line-pd-l1-positive-nsclc-positive-overall-survival-results-from-harmoni-2-presented-at-wclc-2026-302876953.html"},{"id":"sb:o/2962c8f9e654dcd096527099","kind":"observation","label":"PR Newswire · 2026-09-12 · SystImmune, Inc. to Present New Global Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated Non-Small Cell Lung Cancer at WCLC Congress 2026","url":"https://www.prnewswire.com/news-releases/systimmune-inc-to-present-new-global-data-on-iza-bren-izalontamab-brengitecan-in-egfr-mutated-non-small-cell-lung-cancer-at-wclc-congress-2026-302875960.html"},{"id":"sb:o/64ba033de9ed451cd1a13e01","kind":"observation","label":"Clinical Trials Arena · 2026-10-07 · Taiho’s CMO Dr Keer on positive REZILIENT3 data for zipalertinib combo","url":"https://www.clinicaltrialsarena.com/interviews/taihos-cmo-dr-keer-positive-phase-iii-rezilient3-data/"},{"id":"sb:o/cc6e4750cc495c9cf9a0e942","kind":"observation","label":"The ASCO Post · 2026-10-05 · Relapsed or Refractory SCLC Phase I Study of Novel CAR T-Cell Therapy","url":"https://ascopost.com/videos/iaslc-wclc-2026/relapsed-or-refractory-sclc-phase-i-study-of-novel-car-t-cell-therapy/"},{"id":"sb:o/e734daadfcc0da8e4ceb739f","kind":"observation","label":"The ASCO Post · 2026-10-05 · Metastatic PD-L1–High NSCLC Sacituzumab Govitecan/Pembrolizumab","url":"https://ascopost.com/videos/iaslc-wclc-2026/metastatic-pd-l1-high-nsclc-sacituzumab-govitecanpembrolizumab/"},{"id":"sb:o/901df94790a9c91573864ae0","kind":"observation","label":"The ASCO Post · 2026-10-02 · Advanced Lung Cancer Pumitamig Plus Elfetabart Drozuntecan","url":"https://ascopost.com/videos/iaslc-wclc-2026/advanced-lung-cancer-pumitamig-plus-elfetabart-drozuntecan/"},{"id":"sb:o/e7f192ca5c1a7ae7fcc55b5d","kind":"observation","label":"The ASCO Post · 2026-09-30 · Targeting B7-H3 in Second-Line SCLC Treatment Novel ADCs","url":"https://ascopost.com/videos/iaslc-wclc-2026/targeting-b7-h3-in-second-line-sclc-treatment-novel-adcs/"},{"id":"sb:o/872fe75bc02707fa00730ce2","kind":"observation","label":"The ASCO Post · 2026-09-29 · Mobile Lung CT Screening in Resource-Limited Settings BRELT3","url":"https://ascopost.com/videos/iaslc-wclc-2026/mobile-lung-ct-screening-in-resource-limited-settings-brelt3/"},{"id":"sb:o/508b1522bebf1b8218535ae0","kind":"observation","label":"Inside Precision Medicine · 2026-09-24 · Signatera Surges in Liquid Biopsy Race with New Lung Cancer Data and a Japan Approval","url":"https://www.insideprecisionmedicine.com/topics/oncology/signatera-surges-in-liquid-biopsy-race-with-new-lung-cancer-data-and-a-japan-approval/"}],"cursor":"c1.eyJpZCI6InNiOmUvNjM0YTEyMzg4MzE4Mjk4OTVmNDQyMzQ0IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA4VDE3OjMxOjEzLjgyNTk2OCswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with lung cancer (28 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/8f891ee6c9c6a97a81ea7940"},{"kind":"relation","label":"co-mentioned with iaslc (22 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9de40777dc0e4eb43fcff74f"},{"kind":"relation","label":"co-mentioned with cancer center (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e3a650ee67872f51380be45e"},{"kind":"relation","label":"co-mentioned with egfr-mutated (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/476f424da1c4c9db853dc11e"},{"kind":"relation","label":"co-mentioned with her2 (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1fd17fbce3f02b091e830921"},{"kind":"relation","label":"co-mentioned with ros1-positive (11 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/36c95c99f47683daf2a6a346"},{"kind":"relation","label":"co-mentioned with dana-farber cancer institute (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/204dc5f495777192f8b01944"},{"kind":"relation","label":"co-mentioned with her2-mutant (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/8124afd6ecbde3f4741bc18b"},{"kind":"relation","label":"co-mentioned with her3 (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1e3ae4a0aa092e417acb4c8d"},{"kind":"relation","label":"co-mentioned with international association (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e91fb2cc4b0e9412e1340ce4"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/634a1238831829895f442344","mcp":"traverse {\"id\":\"sb:e/634a1238831829895f442344\"}","page":"/entity/wclc/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/634a1238831829895f442344\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/634a1238831829895f442344\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/634a1238831829895f442344\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/634a1238831829895f442344\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}